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SUMMARY
Pancreatic ductal adenocarcinoma (PDA), one of the deadliest human cancers, often involves
somatic activation of K-Ras oncogenes. We report that selective expression of an endogenous
K-RasG12V oncogene in embryonic cells of acinar/centroacinar lineage results in pancreatic intraepi-
thelial neoplasias (PanINs) and invasive PDA, suggesting that PDA originates by differentiation of
acinar/centroacinar cells or their precursors into ductal-like cells. Surprisingly, adult mice become
refractory to K-RasG12V-induced PanINs and PDA. However, if these mice are challenged with
a mild form of chronic pancreatitis, they develop the full spectrum of PanINs and invasive PDA. These
observations suggest that, during adulthood, PDA stems from a combination of genetic (e.g., somatic
K-Ras mutations) and nongenetic (e.g., tissue damage) events.INTRODUCTION
Pancreatic ductal adenocarcinoma (PDA) is one of the
most deadly human tumors, with less than a 3% 5 year
survival rate. Painstaking histological, genetic, and clinical
studies have identified three different ductal preneoplastic
lesions as potential precursors of PDA. They include intra-
ductal papillary mucinous neoplasms (IPMNs) that arise in
the main pancreatic duct or its major branches, pancreatic
intraepithelial neoplasias (PanINs) that originate within in-
tralobular ducts, and mucinous cystic neoplasms (MCN)
that are mucin-producing epithelial neoplasms with aCcharacteristic ovarian-type stroma. All of these preneo-
plastic lesions are likely to represent progressive stages
of the disease (Hruban et al., 2000; Maitra et al., 2005).
Among these preneoplastic lesions, PanINs are the best
characterized at the anatomopathological and molecular
levels (Hruban et al., 2005). For instance, PanINs progress
through well-defined stages (PanIN1A/B to PanIN3) that
display increased architectural and cytological atypia.
Moreover, each of these PanINs has been associated
with specific genetic changes (Hruban et al., 2005). For
instance, about 40% of human PanIN1A/B contain
mutations in K-Ras (review in Tuveson and Hingorani,SIGNIFICANCE
Human PanINs and PDA have been faithfully reproduced in mouse models by expressing an endogenous K-Ras
oncogene in pancreatic lineages during embryonic development. Here, we describe a mouse model that allows
controlled temporal expression of an endogenous K-RasG12V oncogene in cells of acinar and centroacinar origin.
These mice develop the full spectrum of PanINs and invasive PDA when K-RasG12V expression is allowed during
embryonic development. Surprisingly, K-RasG12V expression in adult mice does not result in neoplastic develop-
ment unless they undergo chronic pancreatitis. Previous epidemiological studies have identified pancreatitis as
a risk factor for human PDA. Thus, close monitoring of people who may have suffered pancreatic tissue damage
may help to identify PDA patients in the early stages of the disease.ancer Cell 11, 291–302, March 2007 ª2007 Elsevier Inc. 291
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(Almoguera et al., 1988). These early lesions also overex-
press the HER2 receptor. Increased histological changes
are associated with inactivation or loss of the P16INK4a
tumor suppressor (55% in PanIN2). Finally, high-grade
PanIN3 often display inactivation of P53, loss of SMAD4,
and loss of BRCA2 with various frequencies (Tuveson
and Hingorani, 2005). These genetic alterations are also
found in PDA, thus supporting the concept that PanINs
are precursors of the invasive tumors (Hruban et al.,
2000, 2005).
Considerable efforts have been made during the last
decade to generate animal models that faithfully recapit-
ulate the natural history of human PDA. Most models
involve expression of K-Ras oncogenes (Aguirre et al.,
2003; Brembeck et al., 2003; Grippo et al., 2003; Hingor-
ani et al., 2003; Quaife et al., 1987; Tuveson et al., 2006),
although transgenic expression of other oncogenes such
as polyoma middle T and growth-promoting molecules,
including Shh, HB-EGF, and TGFa, have also been utilized
(Hruban et al., 2006). More recently, the PTEN tumor sup-
pressor has been conditionally deleted in early pancreatic
progenitors (Stanger et al., 2005). Yet, only the model of
Hingorani and coworkers recapitulates the full spectrum
of PanIN lesions most commonly identified in PDA
patients (Hingorani et al., 2003). In this model, an endoge-
nous K-RasG12D oncogene (Jackson et al., 2001) is turned
on during the early stages of embryonic pancreatic devel-
opment by expressing a Cre recombinase under the con-
trol of the Pdx1 or P48 promoters (Kawaguchi et al., 2002;
Kim and MacDonald, 2002). Thus, in this model, expres-
sion of the endogenous K-RasG12D oncogene occurs in
all pancreatic lineages since early (E8.5) embryonic devel-
opment (Hingorani et al., 2003).
Studies aimed at defining the pancreatic lineage re-
sponsible for PDA development have not provided con-
clusive information. Surprisingly, expression of oncogenic
K-Ras transgenes in ductal lineages under the control of
the Cytokeratin 19 promoter has failed to induce PanINs
or PDA (Brembeck et al., 2003). These observations sug-
gest that PDA originates either from early precursors
before they are committed to ductal lineages or by trans-
differentiation of other pancreatic cell types. The latter
hypothesis has been explored by expressing K-Ras onco-
genes in cells of acinar lineage under the control of the
Elastase promoter. Although some of these mice occa-
sionally display low-grade PanINs (P.J.G., unpublished
data), they do not develop high-grade lesions or PDA
(Grippo et al., 2003). More recently, knockin of a K-Ras
oncogene in the locus encoding Mist1, a transcription
factor required for proper acinar organization, induces
invasive and metastatic pancreatic tumors (Tuveson
et al., 2006). Yet, these tumors display mixed histological
characteristics that do not recapitulate the basic proper-
ties of human PDA.
In this study, we have crossed our previously described
conditional K-RasLSLG12Vgeo knocked in mice (Guerra
et al., 2003) with a bitransgenic strain that expresses the
Cre recombinase under the control of the rat Elastase292 Cancer Cell 11, 291–302, March 2007 ª2007 Elsevier Inc.promoter using a tet-off strategy (P.J.G. and E.P.S.,
unpublished data). We report that restricted expression
of this endogenous K-RasG12V oncogene in acinar/
centroacinar cells results in a full range of PanINs and
PDA histologically indistinguishable from those of human
patients (Hruban et al., 2006). Moreover, this model allows
temporal control of K-Ras oncogene expression. Unex-
pectedly, turning on K-RasG12V in adult acinar cells fails
to induce PanINs and PDA. However, if these adult mice
undergo chronic pancreatitis, they develop the full spec-
trum of PanINs and invasive PDA. These observations
raise the possibility that human PDA may require, in
addition to somatic activation of K-Ras oncogenes,
nongenetic events involving tissue damage and/or an
inflammatory response.
RESULTS
Inducible Expression of an Endogenous
K-RasG12V Oncogene in Pancreatic Acinar
and Centroacinar Cells
To express an endogenous K-RasG12V oncogene in pan-
creatic cells of acinar lineage, we crossed our conditional
K-Ras+/LSLG12Vgeo knockin strain (Guerra et al., 2003) with
bitransgenic Elas-tTA/tetO-Cre mice that express the Cre
recombinase under the control of the Elastase promoter in
a tet-off system (P.J.G. and E.P.S., unpublished data). To
verify the pattern of Cre expression in these mice, we
crossed them with the Rosa26R reporter strain (Soriano,
1999). In the absence of doxycycline, Elas-tTA/tetO-Cre/
Rosa26R embryos displayed b-galactosidase activity
exclusively in pancreatic acinar cells, starting at embry-
onic day 16.5 (E16.5) (data not shown). Adult Elas-tTA/
tetO-Cre/Rosa26R mice showed robust b-galactosidase
activity in 20%–30% of acinar cells (Figure 1A). Some cen-
troacinar cells also turned blue in the presence of X-gal
(Figure 1B). However, due to the low number of these
cells, we did not carry out precise quantitative analysis.
More importantly, no b-galactosidase activity was
detected in endocrine islets or in ductal cells of intra-
and interlobular ducts (Figure 1A and Figure S1 in the Sup-
plemental Data available with this article online). As a
control, we did not observe detectable b-galactosidase
activity in pancreata of adult animals continuously fed
with doxycycline (data not shown).
The K-RasLSLG12Vgeo allele carries an IRES-geo cassette
knocked in within its 30 nontranslated sequences (Guerra
et al., 2003). Geo is a bacterial gene that contains se-
quences from LacZ (the gene encoding b-galactosidase)
and neoR (the gene that confers resistance to neomycin)
(Mountford et al., 1994). The internal ribosomal entry site
(IRES) sequences placed 50 of geo allow bicistronic
expression of the chimeric Geo protein and the K-RasG12V
oncoprotein upon Cre-dependent cleavage of the floxed
STOP transcriptional cassette (Figure S2) (Guerra et al.,
2003). This strategy allows identification of K-RasG12V-
expressing cells by staining for b-galactosidase activity
provided by the Geo protein.
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sion
(A and B) b-galactosidase activity as a sur-
rogate marker for Cre recombinase activity
in Elas-tTA/tetO-Cre/Rosa26R mice. X-gal-
stained cryostat sections of adult pancreata
illustrate a patchy pattern of b-galactosidase
activity (blue color) that results from Cre-
mediated recombination of the Rosa26 locus.
(A) X-gal staining is restricted to acinar and
centroacinar cells. Note negative X-gal staining
in ducts (arrowhead) and islet (i) (scale bar,
20 mm). (B) Higher magnification of centroaci-
nar cells positive (black arrowhead) and nega-
tive (white arrowhead) for b-galactosidase
activity (scale bar, 40 mm).
(C) b-galactosidase activity as a surrogate
marker for expression of the K-RasG12V onco-
protein in K-Ras+/LSLG12Vgeo/Elas-tTA/tetO-
Cre mice. X-gal-stained cryostat section of
adult pancreata of K-Ras+/LSLG12Vgeo/Elas-
tTA/tetO-Cre mice not exposed to doxycy-
cline. X-gal staining is restricted to acinar cells.
An intralobular duct (arrowhead) is not stained
(scale bar, 20 mm).
(D) b-galactosidase activity as a surrogate
marker for the expression of wild-type
K-RasG12 protein in K-RasG12geo/G12geo mice.
Note positive X-gal staining in acinar cells as
well as in ductal (arrowheads) and endocrine
(i) cells (scale bar, 20 mm).
(E) Western blot analysis of the expression levels of wild-type K-RasG12 and oncogenic K-RasG12V proteins in MEFs of the indicated genotype as
well as in normal (N) and tumor (PDA) pancreatic tissue obtained from K-Ras+/LSLG12Vgeo/Elas-tTA/tetO-Cre mice. Migration of the K-Ras proteins
is indicated by arrowheads.Sections derived from K-Ras+/LSLG12Vgeo;Elas-tTA/tetO-
Cre mice displayed a spotted pattern of b-galactosidase
staining instead of the uniform staining observed in pan-
creata of Elas-tTA/tetO-Cre/Rosa26R mice (Figure 1).
The reasons for this differential pattern are unknown to
us. However, the percentage of b-galactosidase-positive
acinar and centroacinar cells was similar in both strains,
indicating that the Elastase promotor-driven Cre recombi-
nase cleaved the K-RasLSLG12Vgeo and Rosa26 alleles with
similar efficiencies. As indicated above for Elas-tTA/tetO-
Cre/Rosa26R mice, we did not observe any staining in
ductal and endocrine cells present in sections obtained
from either embryonic or adult K-Ras+/LSLG12Vgeo;Elas-
tTA/tetO-Cre animals (Figure 1C). However, these pancre-
atic cell types displayed b-galactosidase staining in sec-
tions obtained from control K-RasG12geo/G12geo mice
(C.G., A.J.S., M.C., P.D., and M.B., unpublished data),
a strain that constitutively expresses the Geo protein
from the endogenous K-Ras promoter (Figure 1D)
(Figure S2).
Finally, we verified that bicistronic expression of Geo
did not affect expression of the K-RasG12V oncoprotein
in mouse embryonic fibroblasts (MEFs) or in pancreatic
tissue. To this end, we separated normal K-RasG12 and
oncogenic K-RasG12V proteins by taking advantage of
their differential mobility in SDS polyacrylamide gels
(see Experimental Procedures) and determined theirrelative expression levels by western blotting with anti-
K-Ras antibodies. As illustrated in Figure 1E, both
K-Ras+/G12Vgeo MEFs and PDAs obtained from K-Ras+/
LSLG12Vgeo;Elas-tTA/tetO-Cre mice displayed a doublet in
which both bands had the same intensity. Interestingly,
the levels of expression of both K-Ras alleles, K-Ras+
and K-RasG12Vgeo, were significantly increased in tumor
tissue (see below).
Selective Expression of K-RasG12V in Cells
of Acinar/Centroacinar Lineages Induces
PanINs and Invasive PDA
Untreated K-Ras+/LSLG12Vgeo;Elas-tTA/tetO-Cre mice in
which expression of their K-RasG12V oncogenic allele is
turned on during late embryonic development in acinar
and possibly centroacinar cells developed focal morpho-
logical lesions between 1 and 3 months of age. These le-
sions were characterized as acinar-to-ductal metaplasia
according to the criteria described in a recent consensus
pathology report (Figure S3) (Hruban et al., 2006). This re-
port summarizes the basic criteria of the main pancreatic
lesions observed in a number of pancreatic models, in-
cluding the one described here, based on their similarities
to those lesions known to occur in human patients. These
acinar-to-ductal metaplasias (one to ten per pancreata)
were only observed in mice carrying the targeted
K-RasLSLG12Vgeo allele (Figure S3), were positive forCancer Cell 11, 291–302, March 2007 ª2007 Elsevier Inc. 293
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the appearance of PanIN lesions (see below). In older
animals, these acinar-to-ductal metaplasias were associ-
ated with PanIN lesions in about 20% of the cases.
Whether these metaplastic lesions are precursors of Pan-
INs is a controversial issue that has been recently dis-
cussed (Hruban et al., 2006).
K-Ras+/LSLG12Vgeo;Elas-tTA/tetO-Cre mice developed
PanIN lesions that met the criteria defined by Hruban
et al. (2006). Focal low-grade PanINs (PanIN1A) were ob-
served in most (8/11) 3-month-old K-Ras+/LSLG12Vgeo;Elas-
tTA/tetO-Cre mice (Figure 2A). At this time, some animals
(2/11) already contained diffuse PanIN1A/B lesions
(Figure 2B). Three months later, most mice (8/12) had
developed multiple diffuse PanIN1A/B (average of five
lesions per pancreas), including high-grade PanIN2/3
lesions (2/12) and PDA (2/12) in some animals. At 12
months of age, 80% of the mice contained multiple Pan-
INs (average of 15 lesions per pancreas) that had pro-
gressed to high-grade PanIN2/3 lesions (average of nine
per pancreas) (Figure 2C). These PanINs were surrounded
by a stromal reaction characterized by collagen deposits
and fibroblastic proliferation (data not shown). Occasion-
ally, we observed papillary mucinous structures in big
interlobular ducts. Serial analysis of adjacent sections
revealed that these lesions represented intraductal ex-
tension from adjacent intralobular PanINs (Figure 2D;
Figure S4). More importantly, about half of these mice
developed at least one PDA per pancreas. As in human
PDA, these tumors contained abundant desmoplastic
stroma (Figure 2E) and occasionally infiltrated the intesti-
nal wall (Figure 2F). Some of them had lymphovascular
embols (Figure 2G), a predictor of metastatic behavior.
In K-Ras+/LSLG12Vgeo;Elas-tTA/tetO-Cre mice of 6
months of age or older, we occasionally observed areas
of acinar hyperplasia in pancreatic lobules that did not
contain either ductal metaplasia or PanINs (Figure S3C).
Whether these lesions undergo transdifferentiation into
ductal-like lesions such as ductal metaplasia or PanINs
is not known. Yet, they never progress to malignant acinar
cell carcinomas, at least until 20 months of age (data not
shown).
Finally, all PanIN and PDA cells displayed b-galactosi-
dase activity indicating that these lesions arose from cells
expressing the oncogenic K-RasG12Vgeo allele. b-galacto-
sidase expression was also detected in unaffected aci-
nar/centroacinar cells as well as in metaplastic ducts
(data not shown). However, no staining was detected in
normal ductal cells, even in those cases in which they
were adjacent to the PanIN (Figure 2H). Interestingly, the
levels of b-galactosidase activity increased with PanIN
grade to reach the highest levels in PDA (Figures 2I and
2J). These results are in agreement with those obtained
by western blot analysis (Figure 1E). Since we observed
overexpression of both alleles (Figure 1E) in the absence
of overt K-Ras gene amplification (unpublished data), the
increased levels of b-galactosidase expression observed
during tumor progression must be a consequence of in-
creased transcriptional activity on the K-Ras locus.294 Cancer Cell 11, 291–302, March 2007 ª2007 Elsevier Inc.Characterization of K-RasG12V-Induced PanINs
PanINs of K-Ras+/LSLG12Vgeo;Elas-tTA/tetO-Cre mice have
similar properties to those identified in human patients.
They contained abundant mucin (Figure 3A) and immuno-
stained for Cytokeratin 19 (Figure 3B), underscoring their
ductal nature. PanINs often contained scattered endo-
crine cells (Figure 3C), a property also observed in human
Figure 2. K-Ras+/LSLG12Vgeo/Elas-tTA/tetO-Cre Mice Develop
PanIN Lesions and Invasive PDA
(A) Focal PanIN1A characterized by columnar cells filled with mucin
(H&E) (scale bar, 20 mm).
(B) Diffuse low-grade PanIN. Arrowhead shows a PanIN1B (H&E) (scale
bar, 20 mm).
(C) Representative focal PanIN3 (H&E) (scale bar, 20 mm).
(D) Intralobular PanIN1A (asterisk) extending into an interlobular duct
(arrowheads) (H&E) (scale bar, 20 mm).
(E) Poorly differentiated invasive PDA with desmoplastic stroma. Pan-
INs are frequently found at the edges of the tumor (arrowhead) (H&E)
(scale bar, 100 mm).
(F) Invasion of the intestinal wall by a PDA (H&E) (scale bar, 50 mm).
(G) Lymphovascular embol (arrowhead) in the peripancreatic fat tissue
(H&E) (scale bar, 20 mm).
(H) b-galactosidase staining in a PanIN1A that extends into an interlob-
ular duct. Note the sharp transition (arrowheads) between PanIN
(stained) and ductal (unstained) cells (scale bar, 20 mm).
(I) b-galactosidase staining in PanIN2 lesion (scale bar, 20 mm).
(J) b-galactosidase staining in a PDA (scale bar, 50 mm).
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INs contained cells with acinar markers (Figures 3D and
3E). These structures may reflect a transient stage in
PanIN formation in which some cells have not yet lost their
acinar markers. In addition, some PanINs coexpressed
both acinar and ductal markers, suggesting incomplete
commitment to either lineage (Figure 3F). PanINs immuno-
stained for Pdx1, an embryonic marker retained in adult
endocrine islets but not in normal exocrine cells (Figure 3G)
(Offield et al., 1996). Finally, these PanINs were also pos-
itive for Hes1, a marker for the Notch pathway also identi-
fied in human pancreatic tumors (Figure 3H) (Miyamoto
et al., 2003).
Figure 3. Histological Characterization of PanIN Lesions
(A) Mucin content of a diffuse PanIN1A revealed by diastase-PAS
staining (scale bar, 20 mm).
(B) Cytokeratin 19 immunoreactivity in a diffuse PanIN1A and in a
normal duct (arrowhead) (scale bar, 20 mm).
(C) Insulin immunostained cells within a PanIN1A (arrowheads) and an
endocrine islet (i) (scale bar, 20 mm).
(D) Chymotrypsin expression in columnar cells (arrowhead) within
a PanIN1A containing residual chymotrypsin-expressing acinar cells
(scale bar, 20 mm).
(E) Low-grade PanIN lesion stained for diastase-PAS displaying cells
immunoreactive for amylase (brown color, arrowheads). Neighboring
acini stained for amylase are indicated by arrows (scale bar, 20 mm).
(F) Diffuse low-grade PanIN displaying both acinar (amylase, blue color)
and ductal (cytokeratin 19, brown color) markers (scale bar, 20 mm).
(G) Diffuse PanIN1A showing nuclear Pdx1 immunostaining. Endocrine
cells in an adjacent islet (i) serve as positive control (scale bar, 20 mm).
(H) Diffuse PanIN1A exhibiting nuclear Hes1 immunoreactivity (scale
bar, 20 mm). Normal pancreatic cells showed low levels of Ki67 stain-
ing. The frequency of Ki67-positive cells remained low in
low-grade PanINs to increase as they progressed to
high-grade lesions (Figure 4A). PanINs also expressed
a number of other proliferation-associated markers such
as phospho-Erk (pERK) and Cyclin D1 (Figures 4C and
4E). In the case of Ki67 and Cyclin D1, positive cells
appeared scattered within the PanIN. A similar pattern of
expression was observed for cyclooxygenase-2 (Cox2)
(Figure 4G). In contrast, pERK immunoreactivity appeared
uniformly distributed throughout the PanIN (Figure 4C). In-
terestingly, pERK immunoreactivity could not be observed
in normal ductal cells, even in ducts adjacent to PanIN le-
sions (Figure S5). In PDA, pERK was also found uniformly
distributed in all tumoral but not stromal cells (Figure 4D).
In addition, expression of Ki67, Cyclin D1, and Cox2 in
Figure 4. Signaling Pathways in PanINs and PDA
(A and B) Ki67 immunostaining (brown nuclei). The mucin content of
the PanIN lesion (A) is highlighted by PAS staining. Arrowheads help
to identify Ki67 positive cells (scale bars, 20 mm).
(C and D) Phospho-Erk immunostaining in PanIN1B and PDA (scale
bars, 20 mm).
(E and F) Cyclin D1 immunostaining in PanIN1A and PDA (scale bars,
20 mm).
(G and H) Cyclooxygenase-2 immunoreactivity in PanIN1B and PDA
(scale bars, 20 mm). In PDA, immunostaining is observed in tumor cells
(arrowheads) and in the stroma (asterisk).
(I and J) P53 immunostaining in PanIN2 and PDA (scale bars, 20 mm).Cancer Cell 11, 291–302, March 2007 ª2007 Elsevier Inc. 295
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cells (Figures 4B, 4F, and 4H). Finally, P53 nuclear stain-
ing, indicative of P53 inactivation (Bartek et al., 1991),
was observed in some but not all high-grade PanINs,
mostly PanIN3. Yet, PDAs were uniformly positive for
P53 staining, indicating that P53 inactivation is a late event
in the development of PDA (Figures 4I and 4J).
Loss of P53 Confers Metastatic Properties
to K-RasG12V-Induced PDA
To assess the cooperation between K-RasG12V expression
and P53 inactivation, a frequent mutation found in human
PDA (Hruban et al., 2000), K-Ras+/LSLG12Vgeo;Elas-tTA/
tetO-Cre mice were crossed to P53/ animals (Done-
hower et al., 1992). Half of the resulting K-Ras+/LSLG12Vgeo;
Elas-tTA/tetO-Cre;P53+/ mice died before 6 months of
age, and none of them survived more than a year (Fig-
ure 5A). All mice (n = 17) developed moderately to poorly
differentiated PDAs (often more than one per mouse) that
invade surrounding tissues such as duodenum and stom-
ach. Moreover, these animals presented peritoneal im-
plants; perineural extension, a feature frequently found in
human PDA; and metastases affecting liver, diaphragm,
lung, lymph nodes, and spleen that are morphologically
similar to their primary tumor (Figures 5B–5E).
Figure 5. P53 Deficiency Cooperates with K-RasG12V to
Induce Metastatic PDA
(A) Survival of K-Ras+/LSLG12Vgeo;Elas-tTA/tetO-Cre (closed circles)
and K-Ras+/LSLG12Vgeo;Elas-tTA/tetO-Cre;P53+/ (open circles) mice.
(B–E) H&E-stained paraffin sections of (B) liver metastasis (arrowhead)
(scale bar, 50 mm); (C) lung micrometastasis (arrowhead) (scale bar,
20 mm); (D) regional lymph node metastasis (arrowhead) (scale bar,
50 mm); and (E) perineural invasion (asterisk) (scale bar, 20 mm).296 Cancer Cell 11, 291–302, March 2007 ª2007 Elsevier Inc.Adult Pancreatic Cells Are Refractory to
Transformation by the K-RasG12V Oncogene
Previous studies have indicated that widespread
K-RasG12V expression in young mice efficiently induces
lung adenomas and adenocarcinomas, but few pancre-
atic lesions (Guerra et al., 2003). Indeed, careful analysis
of K-Ras+/LSLG12Vgeo;RERTert/ert mice treated for up to
12 weeks with 4-OHT only resulted in low-grade PanINs
in a small percentage of animals in spite of widespread
expression of the K-RasG12Vgeo allele in many cell types,
including pancreatic acinar and ductal cells (C.G.,
A.J.S., M.C., P.D., and M.B., unpublished data). To exam-
ine whether postnatal pancreata might be more resistant
to neoplastic development, we fed doxycycline to preg-
nant K-Ras+/LSLG12Vgeo;Elas-tTA/tetO-Cre mice and their
offspring until they were 10 days old (P10) to prevent ex-
pression of the K-RasG12Vgeo allele. Removal of doxycy-
cline from the drinking water at P10 resulted in the expres-
sion of this allele as determined by b-galactosidase
staining (Figure S6A). These K-Ras+/LSLG12Vgeo;Elas-tTA/
tetO-Cre mice developed PanIN lesions histologically in-
distinguishable from those described above, albeit with
significantly increased latency. For instance, at 6 months
of age, only one-third of the mice (4/12) displayed focal
PanIN1A lesions. Likewise, at 12 months of age, only
37% of the mice (6/16) presented high-grade PanIN2/3
lesions, and only two of them (12%) had PDA.
Maintaining doxycycline in the drinking water for
2 months allowed us to turn on K-RasG12Vgeo expression
in pancreata of adult mice (P60). Analysis of b-galactosi-
dase activity revealed that K-RasG12V was expressed in
about 20% of adult acinar cells, a percentage similar to
that observed in mice not exposed to doxycycline
(Figure S6B). Surprisingly, these mice did not develop ob-
vious histological alterations in their pancreata, including
acinar-to-ductal metaplasia and low-grade PanINs even
when they were examined 6 (n = 8) or 12 (n = 3) months
later. Moreover, their acinar cell compartment did not
show significant differences in their proliferation rates
when compared with control K-Ras+/+;Elas-tTA/tetO-Cre
littermates also exposed to doxycycline until P60 (data
not shown). These observations indicate that expression
of the K-RasG12V oncogene has few, if any, consequences
for adult acinar cells, at least in the context of an otherwise
normal pancreas (see below).
Chronic Pancreatitis Induces PanINs and PDA in
Adult Mice Expressing the K-RasG12V Oncogene
In humans, one of the main risk factors for the develop-
ment of PDA is chronic pancreatitis (Lowenfels et al.,
1993; Malka et al., 2002). Therefore, we decided to inter-
rogate whether chronic pancreatitis may cooperate with
K-RasG12Vgeo expression in inducing PanIN lesions and
PDA. To this end, P30 K-Ras+/+;Elas-tTA/tetO-Cre (n =
12) and K-Ras+/LSLG12Vgeo;Elas-tTA/tetO-Cre (n = 15)
mice exposed to doxycycline since conception were
chronically treated with low doses of caerulein (see Exper-
imental Procedures). Caerulein is a cholecystokinin ana-
log that induces secretion of pancreatic enzymes and,
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either acute or mild forms of pancreatitis (Willemer et al.,
1992; Yoo et al., 2005). These caerulein-treated mice
were continuously fed doxycycline for another month (until
P60) to avoid recombination of the K-RasLSLG12Vgeo allele
until the mice reached adulthood. Caerulein treatment did
not affect the onset of K-RasG12Vgeo expression as deter-
mined by the absence of b-galactosidase staining in caer-
ulein-treated P60 K-Ras+/LSLG12Vgeo;Elas-tTA/tetO-Cre
animals (data not shown).
One month after doxycycline withdrawal, P90 mice, re-
gardless of genotype, displayed atrophic acini (about
20%) and mild panlobular lesions characteristic of chronic
pancreatitis (Figures S7A and S7B). These atrophic acini
had enlarged lumen and occasional focal cuboidal meta-
plasia. More importantly, histologically normal acini dis-
played a high proliferative index with 20%–30% of acinar
cells positive for Ki67 staining versus less than 1% in un-
treated mice (Figures S7C and S7D). No such increase
in Ki67 staining was observed in ductal or endocrine cells.
Moreover, acini of caerulein-treated mice showed slightly
increased levels of apoptosis (data not shown). In addi-
tion, pancreata derived from both cohorts of mice
presented sparse inflammatory infiltrates.
At 5 months of age, the histological differences between
K-Ras+/LSLG12Vgeo;Elas-tTA/tetO-Cre and control mice be-
came more evident. Pancreata of K-RasG12Vgeo-express-
ing mice displayed more severe acinar atrophy and in-
creased fibrosis (Figure 6A). They also showed frequent
acinar-to-ductal metaplasia as well as multifocal meta-
plastic ducts with atypical nuclear features and luminal
budding suggestive of a premalignant behavior (Fig-
ure 6B). These lesions expressed Cytokeratin 19 and
were only observed in the context of K-RasG12Vgeo expres-
sion and chronic pancreatitis. More importantly, half of
these mice had already developed focal and diffuse low-
grade PanIN lesions (data not shown).
At 8 months of age, the cohort expressing the onco-
genic K-RasG12V allele (n = 6) displayed an exacerbated
acinar atrophy with only 20% of their parenchyma corre-
sponding to acinar cells as determined by chymotrypsin
immunostaining as well as multifocal ductal atypia and
severe fibrosis (Figure 6C). Caerulein-treated control
K-Ras+/+;Elas-tTA/tetO-Cre mice also displayed acinar
atrophy but only in about half of their acinar parenchyma.
More importantly, caerulein-treated K-Ras+/LSLG12Vgeo;
Elas-tTA/tetO-Cre animals had multiple PanIN lesions
(an average of 33 per mouse), of which one-fifth were
high-grade PanIN2/3. These lesions were often panlobular
(Figure 6D) and extended into the big interlobular ducts
(Figure 6E). Finally, one-third of the K-RasG12V-expressing
mice had already developed invasive PDAs (Figure 6F).
Similar results were observed 12 months after turning on
K-RasG12V expression. No PanINs or PDA were observed
in caerulein-treated control K-Ras+/+;Elas-tTA/tetO-Cre
mice (n = 4).
Chronic pancreatitis also served as a powerful
tumor promoter in K-Ras+/LSLG12Vgeo;Elas-tTA/tetO-Cre
mice that expressed the K-RasG12Vgeo oncogenicallele during embryogenesis. Caerulein treatment of
K-Ras+/LSLG12Vgeo;Elas-tTA/tetO-Cre mice not exposed
to doxycycline (n = 8) resulted in a significantly faster de-
velopment of high-grade PanIN lesions and invasive PDA
than in littermates not treated with caerulein. At 5 months
of age, a time when only 15% of mice not suffering from
chronic pancreatitis had developed high-grade PanINs,
all caerulein-treated animals presented diffuse ductal
metaplasia along with multiple high-grade PanINs (more
than ten per mice). Moreover, half of the caerulein-treated
mice had invasive PDA with desmoplastic stroma. At 8
months of age, all caerulein-treated K-Ras+/LSLG12Vgeo;
Elas-tTA/tetO-Cre mice had to be sacrificed due to the
presence of multifocal in situ and invasive PDAs. A sum-
mary of the relative incidence of PanIN lesions and PDA
observed in mice described throughout this study is pro-
vided in Figure 7.
Figure 6. Chronic Pancreatitis Induces PanIN and PDA
Lesions in K-Ras+/LSLG12Vgeo;Elas-tTA/tetO-Cre, but Not in
Control K-Ras+/+;Elas-tTA/tetO-Cre Adult Mice
(A) Pancreata of a 3-month-old, caerulein-treated K-Ras+/+;Elas-tTA/
tetO-Cre mouse showing acinar atrophy with distended lumen and
loss of apical granulations (arrows). Cuboidal metaplasia (arrowheads)
and increased fibrosis with sparse inflammatory infiltrates (asterisk)
are shown (H&E) (scale bar, 20 mm).
(B) Metaplastic ducts with atypical nuclear features and luminal
budding in a 5-month-old, caerulein-treated K-Ras+/LSLG12Vgeo;Elas-
tTA/tetO-Cre mouse (H&E) (scale bar, 20 mm).
(C) Severe acinar atrophy attested by chymotrypsin immunostaining in
an 8-month-old, caerulein-treated K-Ras+/LSLG12Vgeo;Elas-tTA/tetO-
Cre mouse (scale bar, 20 mm).
(D) Panlobular PanINs in an 8-month-old, caerulein-treated
K-Ras+/LSLG12Vgeo;Elas-tTA/tetO-Cre mouse (H&E) (scale bar, 20 mm).
(E) PanIN lesion extending into an interlobular duct (arrowhead) in an
8-month-old, caerulein-treated K-Ras+/LSLG12Vgeo;Elas-tTA/tetO-Cre
mouse (H&E) (scale bar, 20 mm).
(F) Poorly differentiated invasive PDA with desmoplastic stroma in an
8-month-old, caerulein-treated K-Ras+/LSLG12Vgeo;Elas-tTA/tetO-Cre
mouse. Low-grade PanIN lesions are present at the edge of the tumor
(arrowhead) (H&E) (scale bar, 50 mm).Cancer Cell 11, 291–302, March 2007 ª2007 Elsevier Inc. 297
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Thick boxes indicate the period of expression of the oncogenic K-RasG12Vgeo allele. Dotted boxes indicate caerulein treatment. The incidence of
PanIN lesions and PDA at various times is indicated in parenthesis. Met, metastatic PDAs. The percentage of mice dead at 12 months of age is
indicated in the right column.Inflammatory Response
Caerulein-treated mice, regardless of genotype, devel-
oped innate and adaptive inflammatory responses. Two
months after caerulein treatment, K-Ras+/LSLG12Vgeo;
Elas-tTA/tetO-Cre and control K-Ras+/+;Elas-tTA/tetO-
Cre mice displayed intra- and interlobular-mixed inflam-
matory infiltrates consisting of T cells (CD3+) and macro-
phages (F4/80+) associated with B cells (Pax5+). The acute
inflammatory component was attested by the presence of
neutrophilic and eosinophilic granulocytes (Myeloperoxi-
dase; MPO+) Pancreata of 5-month-old mice presented
a similar, albeit slightly increased pattern of inflammatory
infiltrates, regardless of genotype. Finally, at 8 months of
age, inflammatory infiltrates remain mostly chronic
(Figure S8) and begin to accumulate plasma cell clusters
(data not shown). K-Ras+/LSLG12Vgeo;Elas-tTA/tetO-Cre
mice, but not control littermates, showed active intralob-
ular fibrosis that became most evident in animals of
5 months of age and older.
Linkage between inflammatory response and cancer
is thought to be primarily mediated by activation of
NF-kB transcription factors (Karin, 2006). NF-kB acti-
vation is often determined by its translocation to the
nucleus (Karin and Ben-Neriah, 2000). Indeed, it has
been previously reported that NF-kB becomes activated
in caerulein-induced chronic pancreatitis (Steinle
et al., 1999). In agreement with these observations, caer-
ulein-induced pancreatitis resulted in strong NF-kB im-
munoreactivity in about 30%–40% of acinar cells in
both K-Ras+/LSLG12Vgeo;Elas-tTA/tetO-Cre (Figures 8A
and 8B) and control K-Ras+/+;Elas-tTA/tetO-Cre mice
(data not shown). Levels of NF-kB expression in ductal
and endocrine cells remained unaltered by caerulein298 Cancer Cell 11, 291–302, March 2007 ª2007 Elsevier Inc.treatment (Figures 8A and 8B). Most positive cells ap-
peared in atrophic acini with loss of apical granulations
and dilated lumen. Only a percentage of these acinar
cells (5%–10%) showed immunoreactivity in their nuclei
(Figures 8B and 8C). Whether these cells also expressed
the oncogenic K-RasG12Vgeo allele remains to be deter-
mined. Yet, since control mice also show this pattern of
NF-kB immunoreactivity, we cannot implicate NF-kB in
PanIN formation. Indeed, low-grade PanINs did not ex-
press significant levels of NF-kB (Figure 8D). However,
it is formally possible that turning on K-RasG12Vgeo ex-
pression in the context of NF-kB-positive cells contrib-
utes to malignant transformation. Finally, NF-kB immu-
nostaining was observed in some high-grade lesions
and in PDA (Figures 8E and 8F). However, this staining
appeared to be mostly cytoplasmic (Figures 8E and 8F),
thus suggesting that NF-kB does not play a role during
progression to PDA.
DISCUSSION
To date, the only mouse model that has faithfully repro-
duced the progressive histological changes responsible
for human PDA involves conditional activation of endoge-
nous K-Ras oncogenes (Hingorani et al., 2003, 2005;
Hruban et al., 2006). Expression of K-RasG12D in pancre-
atic precursors during early embryonic development in-
duces the progressive development of PanINs histologi-
cally indistinguishable from those observed in patients
with PDA (Hingorani et al., 2003, 2005; Aguirre et al.,
2003). We have obtained similar results expressing an
endogenous K-RasG12V oncogene (Guerra et al., 2003) in
a more restricted pancreatic lineage limited to acinar
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support the concept that PanINs and PDA result from dif-
ferentiation of acinar (or possibly centroacinar) cells into
ductal-like cells as a result of K-Ras oncogene expression.
Restricted expression of the endogenous K-RasG12V
oncogene to acinar/centroacinar lineages also results in
a highly metastatic phenotype when combined with loss
of the P53 tumor suppressor. Thus, tumors derived from
acinar/centroacinar cells or their precursors can also
acquire the full spectrum of metastatic properties charac-
teristic of human PDA. Cooperation of K-Ras oncogene
expression in various settings with additional mutations,
including deletion or inactivation of P53, Ink4a/Arf,
Smad4, TGFbR2, or Smad4, as well as activation of
Hedgehog signaling, also results in a significant accelera-
tion of tumor development and, in some instances, acqui-
sition of metastatic properties (Aguirre et al., 2003;
Bardeesy et al., 2006; Hingorani et al., 2005; Ijichi et al.,
2006; Pasca di Magliano et al., 2006).
The use of a tet-off strategy to express a Cre recombi-
nase has allowed us to control the temporal expression
of the targeted K-RasG12V oncogene at any time from
embryonic development (E16.5) to adulthood by simply
removing doxycycline from the drinking water of these an-
Figure 8. NF-kB Expression in Caerulein-Treated K-Ras+/
LSLG12Vgeo;Elas-tTA/tetO-Cre Mice
(A) NF-kB immunostaining in pancreata of an untreated 8-month-old
mouse. Arrowhead shows strong NF-kB expression in normal ductal
cells. Acinar and endocrine cells are unstained (scale bar, 20 mm).
(B) NF-kB expression in a littermate treated with caerulein. Few acinar
cells display nuclear straining (arrow). Strong NF-kB expression in nor-
mal ductal cells is indicated by an arrowhead (scale bar, 20 mm).
(C) Higher magnification of distended atrophic acini showing cytoplas-
mic and/or nuclear-positive NF-kB immunostaining (scale bar, 20 mm).
(D) Lack of NF-kB expression in a PanIN1A lesion. A neighboring aci-
nus shows cytoplasmic NF-kB immunoreactivity (arrowhead) (scale
bar, 20 mm).
(E) NF-kB immunoreactivity in a high-grade PanIN (scale bar, 20 mm).
(F) NF-kB immunoreactivity in a PDA (scale bar, 20 mm).imals. Doxycycline removal allows expression of the Elas-
tase-driven Cre recombinase, which converts the silent
K-RasLSLG12Vgeo allele into the transcriptionally active
K-RasG12Vgeo allele. This strategy has made it possible to
evaluate the effect of K-Ras oncogenes during postnatal
development. Interestingly, turning on K-RasG12V expres-
sion in pancreata of young (P10) mice significantly re-
duces the incidence of PanINs, especially those of high
grade. In addition, it also decreases the occurrence of
PDA. More importantly, when K-RasG12V expression is de-
layed until adulthood, neither PanINs nor PDA is induced.
These results are not due to decreased numbers of acinar
cells expressing the K-RasG12Vgeo allele since the number
of K-RasG12Vgeo-expressing cells in adult pancreata ap-
pears to be independent of the timing at which Cre acti-
vates expression of the silent K-RasLSLG12Vgeo allele. If
PanINs and PDA originate by misdifferentiation of acinar
(and/or centroacinar) progenitors, our results would sug-
gest that the resistance of adult mice to K-Ras-induced
PDA is a consequence of limited numbers of acinar/cen-
troacinar progenitors in the adult pancreas. Alternatively,
if PanINs and PDA PanINs arise by transdifferentiation
of acinar (and/or centroacinar) cells, our results would
suggest that adult acinar cells are less prone to transdif-
ferentiate than those of embryonic (E16.5) or postnatal
(P10) animals.
Adult mice became permissive to K-RasG12V-induced
PanINs and PDA if they suffered a mild form of chronic pan-
creatitis. PanIN formation is completely dependent on K-
RasG12Vgeo expression and follows a defined progression
from low- to high-grade lesions that ends up in the appear-
ance of invasive PDA. These observations indicate that
chronic pancreatitis allows recapitulation in adult mice of
the multistep transformation process observed when
K-Ras oncogenes are expressed during embryonic devel-
opment. A possible explanation for these observations is
that pancreatitis increases the pool of K-RasG12V-suscep-
tible cells, most likely acinar precursors. Additional sup-
port for this hypothesis is provided by the strong tumor-
promoting effect that chronic pancreatitis exerts in
K-Ras+/LSLG12Vgeo;Elas-tTA/tetO-Cre mice that express
K-RasG12Vgeo in embryonic precursors. However, we
cannot rule out the possibility that pancreatitis may induce
and/or facilitate transdifferentiation of mature acinar cells,
making them susceptible to transformation by K-Ras
oncogenes.
These observations may have important implications
regarding the ontogeny of human PDA. The timing at
which K-Ras mutations presumably initiate PDA in
humans is not known (Kern, 2000; Kimura et al., 1998).
Yet, it is unlikely that K-Ras oncogenes are mutated during
embryonic or early postnatal development since there are
no reports of pediatric PDA. Epidemiological studies have
established a firm link between chronic pancreatitis and
a percentage of human PDA (Lowenfels et al., 1993; Malka
et al., 2002; Whitcomb and Pogue-Geile, 2002). Thus, it is
tempting to speculate that human PDA may also stem
from a combination of somatic mutations, mainly involving
K-Ras oncogenes and nongenetic insults such as mild orCancer Cell 11, 291–302, March 2007 ª2007 Elsevier Inc. 299
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in temporary tissue damage.
As observed in human patients, experimentally induced
chronic pancreatitis results in acinar atrophy accompa-
nied by increased proliferation of acinar cells, which is
most likely a compensatory response. In addition, caeru-
lein treatment induces innate and adaptive inflammatory
responses characterized by invasion of macrophages
and lymphocytes, respectively. These immune cells are
also likely to induce cell proliferation by releasing inflam-
matory cytokines. This proliferative response may either
amplify a pool of acinar progenitors susceptible to trans-
formation by K-Ras oncogenes and/or facilitate transdif-
ferentiation of mature acinar cells. However, our studies
cannot discern which one of these proliferative stimuli
contributes (and, if so, to what extent) to the generation
of K-Ras oncogene-induced PanINs.
Previous studies have shown that caerulein treatment
induces immediate nuclear NF-kB activity in acinar cells
well before the onset of cellular injury including activation
of an immune response (Steinle et al., 1999). In our model,
nuclear translocation of NF-kB preceded PanIN forma-
tion. Moreover, no NF-kB immunostaining could be
observed in PanIN lesions. Yet, our results cannot exclude
the possibility that NF-kB activity may facilitate K-
RasG12V-induced transformation of acinar cells. However,
it is unlikely that NF-kB plays a role during tumor progres-
sion as previously described in colitis-associated colon
cancer (Greten et al., 2004), since NF-kB immunostaining
in high-grade PanINs and PDA remains mostly located in
the cytoplasm. Ablation of NF-kB activators, such as
IKKb (Maeda et al., 2005), and/or inhibition of the immune
response by genetic or pharmacological means should
help to ascertain what mechanisms (proliferation as a
direct response to tissue damage versus an inflammatory
response) make adult K-Ras+/LSLG12Vgeo;Elas-tTA/tetO-
Cre mice susceptible to PDA.
EXPERIMENTAL PROCEDURES
Mouse Strains
Compound K-Ras+/LSLG12Vgeo;Elas-tTA/tetO-Cre mice were generated
by crossing the K-Ras+/LSLG12Vgeo strain, previously designated as
K-ras+/V12 (Guerra et al., 2003), with two strains carrying the
Elastase-tTA (P.J.G. and E.P.S., unpublished data) and the tetO-
PhCMV-Cre (Saam and Gordon, 1999) transgenes, respectively. The
Elastase-tTA strain was generated by fusing a 205 bp DNA fragment
containing the rat Elastase promoter and enhancer regions (Ornitz
et al., 1987) with sequences encoding the tTA transactivator and
a 600 bp fragment derived from the 30 UTR of the human growth hor-
mone gene that provided the polydenylation signal (P.J.G. and E.P.S.,
unpublished data). These transgenes allow expression of the bacterial
Cre recombinase in cells normally expressing the Elastase gene under
the negative control of doxycycline (tet-off system) (Furth et al., 1994).
Doxycycline (2 mg/ml, Sigma) was provided in the drinking water as
a sucrose (5% w/v) solution to pregnant mothers from the time of con-
ception and to their offspring until the time required to turn on
K-RasG12V expression (P10 or P60). Cre-mediated recombination
removes the transcriptional STOP cassette present in the
K-RasLSLG12Vgeo allele to allow bicistronic expression of K-RasG12V
and Geo proteins (Guerra et al., 2003). Geo is a chimeric protein
containing bacterial b-galactosidase and neomycin resistance se-300 Cancer Cell 11, 291–302, March 2007 ª2007 Elsevier Inc.quences (Mountford et al., 1994). Chronic pancreatitis was induced
by treatment with caerulein (Sigma), a cholecystokinin analog
(Willemer et al., 1992; Yoo et al., 2005). Caerulein was administered
as a single daily intraperitoneal injection (0.1 ml of a 50 mg/ml solution
in saline) 5 days per week during the duration of the study. These ex-
periments were approved by the CNIO Ethical Committee and per-
formed in accordance with the guidelines for Ethical Conduct in the
Care and Use of Animals as stated in The International Guiding Princi-
ples for Biomedical Research Involving Animals, developed by the
Council for International Organizations of Medical Sciences (CIOMS).
Histopathology and Immunohistochemistry
Specimens were fixed in 10% buffered formalin and embedded in par-
affin. For histopathological analysis, pancreata were serially sectioned
(3 mm) and every fifth section was stained with hematoxylin and eosin
(H&E). Remaining sections were used for immunohistochemical stud-
ies with the primary antibodies indicated with their specifications in Ta-
ble S1. Following incubation with the primary antibodies, positive cells
were visualized using 3,3-diaminobenzidine tetrahydrochloride plus
(DAB+) as a chromogen. Staining for mucin content was carried out
by using diastase-PAS. X-gal staining of cryosections (10 mm) (2–4 hr
for tissues of Elas-tTA/tetO-Cre/Rosa26R mice and pancreata of tu-
mor-bearing K-Ras+/LSLG12Vgeo;Elas-tTA/tetO-Cre animals and up to
48 hr for normal tissues of K-Ras+/LSLG12Vgeo;Elas-tTA/tetO-Cre mice)
was carried out as previously described (Guerra et al., 2003). Counter-
staining was performed with nuclear fast red or hematoxylin.
Western Blot Analysis
Immunoprecipitates were obtained by incubating 500 mg (MEFs) or
1 mg (tissues) of cell extracts with the Y13-259 rat monoclonal antibody
(Ab-1, Calbiochem), separated in 15% SDS-PAGE, transferred to nitro-
cellulose filters, and incubated with anti-K-Ras-specific polyclonal
antibody F-234 (Santa Cruz Biotechnology). F-234 antibodies were
detected with a polyclonal goat anti-mouse horseradish peroxidase-
linked secondary antibody and visualized with enhanced chemiolumi-
niscent system (ECL Plus, Amersham). Wild-type K-RasG12 and onco-
genic K-RasG12V proteins display different migration (Joyce et al., 1989).
Supplemental Data
The Supplemental Data include eight supplemental figures and one
supplemental table and can be found with this article online at http://
www.cancercell.org/cgi/content/full/11/3/291/DC1/.
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